Ra Capital Management, L.p. bought $292k of ARTV
director, owner at Artiva Biotherapeutics, Inc.. 32,876 shares at an average of $8.89, traded Jun 25, 2026, filed Jun 29, 2026.
Score components
- +15RoleDirector
- +14Trade size$292k at market
- -5Relative to holdingsUnder 1% of holdings (0.2%)
- +8Price context34% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying4 buys in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000711, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +31,000 | $8.88 | $275k | 16,794,043 | Jun 29, 2026 |
| Jun 26, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,876 | $8.98 | $17k | 16,795,919 | Jun 29, 2026 |
Related signals
Other insiders at Artiva Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $169k 23,463 shares | -2% | |
| 56Moderate | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $422k 61,696 shares | -4% | |
| 30Weak | Artiva Biotherapeutics, Inc. | Subhashis Banerjee Chief Medical Officer | $7,514 1,099 shares | -1% | |
| 42Moderate | Artiva Biotherapeutics, Inc. | Jennifer Bush COO, CLO, Compliance Officer | $57k 8,370 shares | -2% | |
| 38Weak | Artiva Biotherapeutics, Inc. | Christopher Horan Chief Tech Operations Officer | $71k 10,340 shares | -3% | |
| 33Weak | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $256k 23,429 shares | -2% | |
| 61Notable | Artiva Biotherapeutics, Inc. | Fred Aslan Chief Executive Officer | $690k 61,888 shares | -4% | |
| 30Weak | Artiva Biotherapeutics, Inc. | Subhashis Banerjee Chief Medical Officer | $12k 1,100 shares | -1% | |
| 45Moderate | Artiva Biotherapeutics, Inc. | Jennifer Bush COO, CLO, Compliance Officer | $94k 8,391 shares | -2% | |
| 40Moderate | Artiva Biotherapeutics, Inc. | Christopher Horan Chief Tech Operations Officer | $116k 10,366 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.